<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01528826</url>
  </required_header>
  <id_info>
    <org_study_id>NVBOX</org_study_id>
    <nct_id>NCT01528826</nct_id>
  </id_info>
  <brief_title>Salvage Chemotherapy of Vinorelbine Plus Oxaliplatin in Metastatic Triple-negative Breast Cancer:a Prospective Trial</brief_title>
  <acronym>NVBOX</acronym>
  <official_title>A Prospective Phase II Trial of Vinorelbine Plus Oxaliplatin in Pretreated Metastatic Triple-negative Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fudan University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fudan University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the efficacy and safety of vinorelbine plus&#xD;
      oxaliplatin in pretreated metastatic triple-negative breast cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Triple-negative breast cancer is associated with less treatment choices and shorter overall&#xD;
      survival. Both vinorebine and oxaliplatin are effective in metastatic breast cancer. The&#xD;
      investigators designed this trial to evaluate the combination of these two drugs in&#xD;
      pretreated metastatic triple-negative breast cancer.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>December 2011</start_date>
  <completion_date type="Anticipated">July 2013</completion_date>
  <primary_completion_date type="Anticipated">July 2013</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>progression free survival</measure>
    <time_frame>6 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>overall response rate</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>overall survival</measure>
    <time_frame>6 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety and Tolerability</measure>
    <time_frame>6 weeks</time_frame>
    <description>Number of Participants with Adverse Events, Degree of Adverse Events according to CTC4.0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>genetic polymorphisms</measure>
    <time_frame>6 weeks</time_frame>
    <description>To evaluate the relationship of genetic polymorphisms and efficacy.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>NVBOX regimen</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Vinorelbine plus oxaliplatin</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>vinorelbine plus oxaliplatin</intervention_name>
    <description>Vinorelbine 30mg/m2 IVGTT D1 Oxaliplatin 90mg/m2 IVGTT D1; every 2 weeks</description>
    <arm_group_label>NVBOX regimen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Females with age between 18 and 70 years old&#xD;
&#xD;
          2. ECOG performance between 0-2&#xD;
&#xD;
          3. Life expectancy more than 3 months&#xD;
&#xD;
          4. Histological proven unresectable recurrent or advanced breast cancer&#xD;
&#xD;
          5. Triple-negative for estrogen receptor (ER), progestogen receptor (PR), and human&#xD;
             epithelial receptor-2 (HER2) by immunohistochemistry (IHC) test. For patients with ER&#xD;
             negative, PR negative, Her2 two plus, a negative Her2 gene amplification should be&#xD;
             verified with FISH test. Her2 one plus may consider FISH verification.&#xD;
&#xD;
          6. No more than 2 chemotherapy for metastatic breast cancer.&#xD;
&#xD;
          7. At least one measurable disease according to the response evaluation criteria in solid&#xD;
             tumor (RECIST1.1)&#xD;
&#xD;
          8. No anticancer therapy within 4 weeks&#xD;
&#xD;
          9. No neuropathy more than grade I&#xD;
&#xD;
         10. Adequate hematologic, hepatic, and renal function,No serious medical history of heart,&#xD;
             lung, liver and kidney&#xD;
&#xD;
         11. Provision of written informed consent prior to any study specific procedures&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant or lactating women (female patients of child-bearing potential must have a&#xD;
             negative serum pregnancy test within 14 days of first day of drug dosing, or, if&#xD;
             positive, a pregnancy ruled out by ultrasound)&#xD;
&#xD;
          2. Women of child-bearing potential, unwilling to use adequate contraceptive protection&#xD;
             during the course of the study&#xD;
&#xD;
          3. Treatment with an investigational product within 4 weeks before the first treatment&#xD;
&#xD;
          4. Symptomatic central nervous system metastases&#xD;
&#xD;
          5. Other active malignancies (including other hematologic malignancies) or other&#xD;
             malignancies, except for cured nonmelanoma skin cancer or cervical intraepithelial&#xD;
             neoplasia.&#xD;
&#xD;
          6. Patient having a history of clinically significant cardiovascular, hepatic,&#xD;
             respiratory or renal diseases, clinically significant hematological and endocrinal&#xD;
             abnormalities, clinically significant neurological or psychiatric conditions&#xD;
&#xD;
          7. Uncontrolled serious infection&#xD;
&#xD;
          8. Previous administration of vinorelbine&#xD;
&#xD;
          9. Patients with bad compliance&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhonghua Wang, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fudan University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Leiping Wang, MD</last_name>
    <phone>+862164175590</phone>
    <phone_ext>8908</phone_ext>
    <email>leipingwang@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fudan University Cancer Center</name>
      <address>
        <city>Shanghai</city>
        <state>Shanghai</state>
        <zip>200032</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Leiping Wang, MD</last_name>
      <phone>+862164175590</phone>
      <email>leipingwang@163.com</email>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>February 2012</verification_date>
  <study_first_submitted>January 29, 2012</study_first_submitted>
  <study_first_submitted_qc>February 7, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 8, 2012</study_first_posted>
  <last_update_submitted>February 7, 2012</last_update_submitted>
  <last_update_submitted_qc>February 7, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 8, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Fudan University</investigator_affiliation>
    <investigator_full_name>yanfei Liu</investigator_full_name>
    <investigator_title>principal investigator</investigator_title>
  </responsible_party>
  <keyword>metastatic triple-negative breast cancer</keyword>
  <keyword>vinorebine</keyword>
  <keyword>oxaliplatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Vinorelbine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

